Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial

Details 詳細情報について

• CRID

  1360292621537733504

• DOI

  10.1016/s1470-2045(16)30561-7

• ISSN

  14702045

• Web Site

  https://api.elsevier.com/content/article/PII:S1470204516305617?httpAccept=text/xml

  https://api.elsevier.com/content/article/PII:S1470204516305617?httpAccept=text/plain

• Data Source

  • Crossref